Organogenesis Holdings Inc. (NASDAQ: ORGO)

Organogenesis Holdings Inc. is a regenerative medicine and tissue innovations company that develops manufactures and sells products for the advanced wound care surgical and sports medicine markets. The company’s mission is to provide an integrated portfolio of healing and tissue solutions that improve lives while lowering the overall cost of health care. Its products are designed to treat chronic and acute wounds as well as tendon ligament injuries and osteoarthritis symptoms. Several of its marketed products have received premarket approval or 510k clearance from the United States Food and Drug Administration. Organogenesis serves a diverse set of health care customers including hospitals wound care centers government facilities ambulatory surgery centers and physician offices.

Organogenesis generates revenue primarily from the sale of its regenerative medicine products such as Apligraf for venous leg ulcers and diabetic foot ulcers Dermagraft for diabetic foot ulcers though manufacturing is currently suspended PuraPly AM as an antimicrobial barrier for various wound types CYGNUS Dual as a dual layered amniotic membrane VIA Matrix Affinity Novachor and NuShield placental allografts used as protective barriers and extracellular matrix scaffolds. The company also earns revenue from licensing agreements such as the arrangement with Vivex Biologics for the CYGNUS Dual and VIA products and from the sale of PuraForce reinforcement matrix and other surgical products. Additionally Organogenesis receives upfront and milestone payments under its collaboration agreements and pays royalties on net sales of licensed products as defined in those contracts. Sales are made to health care providers in the United States and through distributors in select international markets including Switzerland Saudi Arabia and Kuwait.

The company operates through the following segments: Advanced Wound Care and Surgical & Sports Medicine. Each segment encompasses distinct product families that address specific clinical needs while sharing common manufacturing and regulatory capabilities.

• Advanced Wound Care includes Apligraf a bioengineered bilayered skin substitute with PMA approval for the treatment of venous leg ulcers and diabetic foot ulcers. Dermagraft is a dermal scaffold that supports diabetic foot ulcer healing though its manufacturing is temporarily suspended while the company prepares to transfer production to its newly leased facility in Smithfield Rhode Island. PuraPly AM functions as an antimicrobial barrier made from porcine collagen combined with polyhexamethylene biguanide to manage bioburden across a range of wound types including partial and full thickness wounds pressure ulcers venous ulcers diabetic ulcers and surgical wounds. CYGNUS Dual is a dual layered amniotic membrane that can be stored at room temperature and provides a protective extracellular matrix scaffold for chronic and acute wounds. VIA Matrix Affinity Novachor and NuShield are placental allografts that serve as protective barriers and extracellular matrix scaffolds for various wound sizes and types.

• Surgical & Sports Medicine features NuShield a dehydrated placental allograft used as a surgical barrier and extracellular matrix scaffold to support soft tissue repair. PuraForce is a bioengineered porcine collagen matrix designed for soft tissue reinforcement in procedures such as tendon and ligament repair. Affinity and Novachor are placental allografts that are marketed for acute surgical wounds and for use as protective barriers in the operating room. PuraPly AM and PuraPly SX provide antimicrobial barrier function for open wounds encountered during surgery while PuraPly MZ offers a micronized particulate version that can be applied as a powder or gel. The segment also includes the investigational product ReNu a cryopreserved suspension derived from human amniotic fluid being evaluated in phase three clinical trials for symptomatic knee osteoarthritis with plans to study hip osteoarthritis.

Organogenesis holds a strong position in the regenerative medicine industry due to its broad portfolio of FDA cleared and approved products its in house clinical and reimbursement support and its established relationships with group purchasing organizations. Competitors include other developers of skin substitutes placental based therapies and orthobiologics but the company differentiates itself through the combination of PMA approved 510k cleared products and proven clinical evidence from large trials. The company’s focus on products that address large and growing markets driven by aging populations and rising diabetes and obesity rates further supports its competitive stance. Organogenesis also leverages its proprietary processing methods such as AlloFresh and LayerLoc to maintain the biological activity of its tissue based products. These manufacturing advantages help ensure product consistency and reduce reliance on external suppliers.

The company serves hospitals wound care centers government facilities ambulatory surgery centers and physician offices across the United States. In addition Organogenesis distributes select products through independent agents in Switzerland Saudi Arabia and Kuwait and is evaluating regulatory pathways for potential expansion in the European Union. These customers rely on Medicare Medicaid and private payer reimbursement for the use of its advanced wound care and surgical products. Organogenesis provides in house reimbursement support medical technical assistance and field based medical science liaisons to help clinicians navigate coverage and billing requirements. By maintaining direct relationships with health care providers the company aims to improve product adoption and ensure consistent supply of its regenerative therapies.